Biogen CEO to step down as the drugmaker plans further Aduhelm cost cuts

Read Time:1 Minute, 50 Second


A Biogen facility in Cambridge, Massachusetts.

Brian Snyder | Reuters

Biogen’s Chief Executive Officer Michel Vounatsos is stepping down, at a time the drugmaker is grappling with Medicare restricting coverage for its Alzheimer’s drug Aduhelm to patients in clinical trials.

Vounatsos, who will continue in his role until his successor is appointed, was named as the CEO in 2016 and has been at the helm as Biogen developed and launched several flagship drugs including spinal muscular atrophy drug Spinraza, multiple sclerosis drug Vumerity and most recently Aduhelm .

Biogen said on Tuesday it was looking at substantially eliminating commercial infrastructure related to the Alzheimer’s drug and plans for more cost cuts, in addition to the current program to save $500 million annually.

Coverage for Aduhelm is restricted to patients in clinical trials, and the company said it will retain minimal resources to make the drug available to patients currently on treatment in the US

The company was betting on Aduhelm, the first new treatment for the memory-robbing disease in nearly 20 years, to act as a buffer as its main revenue drivers face rising competition.

However, Aduhelm has faced multiple hurdles after the US Food and Drug Administration approved it last June under an accelerated approval pathway.

Since then, investigations have been launched into the FDA’s decision taken over objections of its own outside advisers, doctors have held back on prescribing the drug and the US Medicare operator in April decided to limit coverage of Aduhelm under the government insurance plan.

“We think the Street will view tough changes as a move in the right direction for the sake of BIIB sentiment, longer-term spend and need to move forward … the changes have been talked about previously … but the timing was not necessarily expected this soon,” Jefferies analyst Michael Yee said in a note.

Biogen is now counting on its second Alzheimer’s drug lecanemab, which like Aduhelm, has also been developed with Japanese company Eisai Co. Ltd.

Biogen plans to complete the rolling submission for lecanemab under the accelerated approval pathway in the US in the second quarter.


If you want to know more about business please go to https://updatednews24.com/category/business/

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %
We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners. View more
Cookies settings
Accept
Privacy & Cookie policy
Privacy & Cookies policy
Cookie name Active

Who we are

Suggested text: Our website address is: https://updatednews24.com.

Comments

Suggested text: When visitors leave comments on the site we collect the data shown in the comments form, and also the visitor’s IP address and browser user agent string to help spam detection. An anonymized string created from your email address (also called a hash) may be provided to the Gravatar service to see if you are using it. The Gravatar service privacy policy is available here: https://automattic.com/privacy/. After approval of your comment, your profile picture is visible to the public in the context of your comment.

Media

Suggested text: If you upload images to the website, you should avoid uploading images with embedded location data (EXIF GPS) included. Visitors to the website can download and extract any location data from images on the website.

Cookies

Suggested text: If you leave a comment on our site you may opt-in to saving your name, email address and website in cookies. These are for your convenience so that you do not have to fill in your details again when you leave another comment. These cookies will last for one year. If you visit our login page, we will set a temporary cookie to determine if your browser accepts cookies. This cookie contains no personal data and is discarded when you close your browser. When you log in, we will also set up several cookies to save your login information and your screen display choices. Login cookies last for two days, and screen options cookies last for a year. If you select "Remember Me", your login will persist for two weeks. If you log out of your account, the login cookies will be removed. If you edit or publish an article, an additional cookie will be saved in your browser. This cookie includes no personal data and simply indicates the post ID of the article you just edited. It expires after 1 day.

Embedded content from other websites

Suggested text: Articles on this site may include embedded content (e.g. videos, images, articles, etc.). Embedded content from other websites behaves in the exact same way as if the visitor has visited the other website. These websites may collect data about you, use cookies, embed additional third-party tracking, and monitor your interaction with that embedded content, including tracking your interaction with the embedded content if you have an account and are logged in to that website.

Who we share your data with

Suggested text: If you request a password reset, your IP address will be included in the reset email.

How long we retain your data

Suggested text: If you leave a comment, the comment and its metadata are retained indefinitely. This is so we can recognize and approve any follow-up comments automatically instead of holding them in a moderation queue. For users that register on our website (if any), we also store the personal information they provide in their user profile. All users can see, edit, or delete their personal information at any time (except they cannot change their username). Website administrators can also see and edit that information.

What rights you have over your data

Suggested text: If you have an account on this site, or have left comments, you can request to receive an exported file of the personal data we hold about you, including any data you have provided to us. You can also request that we erase any personal data we hold about you. This does not include any data we are obliged to keep for administrative, legal, or security purposes.

Where we send your data

Suggested text: Visitor comments may be checked through an automated spam detection service.
Save settings
Cookies settings